This high-risk disease carries a gene expression signature similar to that of Ph+ ALL but without the BCR::ABL1 translocation, as well as genomic alterations that activate several types of kinase signaling pathways [7, 8]. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.